Immune Design Corp. (IMDZ), a clinical-stage immunotherapy company, Wednesday said third-quarter net loss was $6.7 million or $0.55 per share compared to loss of $4.0 million or $10.81 per share for the third quarter 2013.
On average, three analysts polled by Thomson Reuters expected a loss of $0.36 per share for the quarter. Analysts' estimates typically exclude special items.
Total revenues improved to $3.54 million from last year's $129 thousand. Analysts expected revenues of $130 thousand.
The company expects to have cash to fund operations for approximately three years, without entering into any additional collaboration agreements or receiving any future milestone payments.
For comments and feedback contact: editorial@rttnews.com
Business News